LISBON (EGMN) - The possibility that incretin-based therapies for type 2 diabetes can cause cancer warrants further investigation, a leading clinical diabetologist has said."Pancreatitis and pancreatic cancer are reported in excess with exenatide and sitagliptin therapy in the FDA AERS [Food and Drug Administration's Adverse Events Reporting System database] in comparison to other diabetes medications," Dr. Peter Butler said at the annual meeting of the European Association for the Study of Diabetes.Using...